Cargando…

Elevated ratio of MMP2/MMP9 activity is associated with poor response to chemotherapy in osteosarcoma

BACKGROUND: Matrix metalloproteinases (MMPs) are crucially involved in the regulation of multiple stages of cancer progression. Elevated MMP levels have been associated with the development of metastases and poor prognosis in several types of cancer. However, the role of MMPs in osteosarcoma and the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunz, Pierre, Sähr, Heiner, Lehner, Burkhard, Fischer, Christian, Seebach, Elisabeth, Fellenberg, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4793522/
https://www.ncbi.nlm.nih.gov/pubmed/26979530
http://dx.doi.org/10.1186/s12885-016-2266-5
_version_ 1782421396319633408
author Kunz, Pierre
Sähr, Heiner
Lehner, Burkhard
Fischer, Christian
Seebach, Elisabeth
Fellenberg, Jörg
author_facet Kunz, Pierre
Sähr, Heiner
Lehner, Burkhard
Fischer, Christian
Seebach, Elisabeth
Fellenberg, Jörg
author_sort Kunz, Pierre
collection PubMed
description BACKGROUND: Matrix metalloproteinases (MMPs) are crucially involved in the regulation of multiple stages of cancer progression. Elevated MMP levels have been associated with the development of metastases and poor prognosis in several types of cancer. However, the role of MMPs in osteosarcoma and their prognostic value is still unclear. Available data are conflicting, most likely due to different technical approaches. We hypothesized that in contrast to total mRNA or protein levels frequently analyzed in previous studies the enzymatic activities of MMPs and their inhibitors the tissue inhibitors of matrix metalloproteinases (TIMPs) are closer related to their biological functions. We therefore aimed to evaluate the reliability of different zymography techniques for the quantification of MMP and TIMP activities in osteosarcoma biopsies in order to investigate their distribution, possible regulation and prognostic value. METHODS: All analyses were done using cryo-conserved osteosarcoma pretreatment biopsies (n = 18). Gene and protein expression of MMPs and TIMPs were analyzed by RT-qPCR and western blot analysis, respectively. Overall MMP activity was analyzed by in situ zymography, individual MMP activities were analyzed by gelatin zymography. Reverse zymography was used to detect and quantify TIMP activities. RESULTS: Strong overall MMP activities could be detected in osteosarcoma pretreatment biopsies with MMP2 and MMP9 as predominant active MMPs. In contrast to total RNA or protein expression MMP2 and MMP9 activities showed significant quantitative differences between good and poor responders. While MMP9 activity was high in the good responder group and significantly decreased in the poor responder group, MMP2 activity showed a reverse distribution. Likewise, significant differences were detected concerning the activity of TIMPs resulting in a negative correlation of TIMP1 activity with MMP2 activity (p = 0.044) and negative correlations of TIMP2 and TIMP3 with MMP9 activity (p = 0.007 and p = 0.006). CONCLUSION: In contrast to mRNA or protein levels MMP and TIMP activities showed significant differences between the analyzed good and poor responder groups. A shift from MMP9 to predominant MMP2 activity is associated with poor response to chemotherapy suggesting that the ratio of MMP2/MMP9 activity might be a valuable and easily accessible marker to predict the response to chemotherapy in osteosarcoma.
format Online
Article
Text
id pubmed-4793522
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47935222016-03-16 Elevated ratio of MMP2/MMP9 activity is associated with poor response to chemotherapy in osteosarcoma Kunz, Pierre Sähr, Heiner Lehner, Burkhard Fischer, Christian Seebach, Elisabeth Fellenberg, Jörg BMC Cancer Research Article BACKGROUND: Matrix metalloproteinases (MMPs) are crucially involved in the regulation of multiple stages of cancer progression. Elevated MMP levels have been associated with the development of metastases and poor prognosis in several types of cancer. However, the role of MMPs in osteosarcoma and their prognostic value is still unclear. Available data are conflicting, most likely due to different technical approaches. We hypothesized that in contrast to total mRNA or protein levels frequently analyzed in previous studies the enzymatic activities of MMPs and their inhibitors the tissue inhibitors of matrix metalloproteinases (TIMPs) are closer related to their biological functions. We therefore aimed to evaluate the reliability of different zymography techniques for the quantification of MMP and TIMP activities in osteosarcoma biopsies in order to investigate their distribution, possible regulation and prognostic value. METHODS: All analyses were done using cryo-conserved osteosarcoma pretreatment biopsies (n = 18). Gene and protein expression of MMPs and TIMPs were analyzed by RT-qPCR and western blot analysis, respectively. Overall MMP activity was analyzed by in situ zymography, individual MMP activities were analyzed by gelatin zymography. Reverse zymography was used to detect and quantify TIMP activities. RESULTS: Strong overall MMP activities could be detected in osteosarcoma pretreatment biopsies with MMP2 and MMP9 as predominant active MMPs. In contrast to total RNA or protein expression MMP2 and MMP9 activities showed significant quantitative differences between good and poor responders. While MMP9 activity was high in the good responder group and significantly decreased in the poor responder group, MMP2 activity showed a reverse distribution. Likewise, significant differences were detected concerning the activity of TIMPs resulting in a negative correlation of TIMP1 activity with MMP2 activity (p = 0.044) and negative correlations of TIMP2 and TIMP3 with MMP9 activity (p = 0.007 and p = 0.006). CONCLUSION: In contrast to mRNA or protein levels MMP and TIMP activities showed significant differences between the analyzed good and poor responder groups. A shift from MMP9 to predominant MMP2 activity is associated with poor response to chemotherapy suggesting that the ratio of MMP2/MMP9 activity might be a valuable and easily accessible marker to predict the response to chemotherapy in osteosarcoma. BioMed Central 2016-03-15 /pmc/articles/PMC4793522/ /pubmed/26979530 http://dx.doi.org/10.1186/s12885-016-2266-5 Text en © Kunz et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Kunz, Pierre
Sähr, Heiner
Lehner, Burkhard
Fischer, Christian
Seebach, Elisabeth
Fellenberg, Jörg
Elevated ratio of MMP2/MMP9 activity is associated with poor response to chemotherapy in osteosarcoma
title Elevated ratio of MMP2/MMP9 activity is associated with poor response to chemotherapy in osteosarcoma
title_full Elevated ratio of MMP2/MMP9 activity is associated with poor response to chemotherapy in osteosarcoma
title_fullStr Elevated ratio of MMP2/MMP9 activity is associated with poor response to chemotherapy in osteosarcoma
title_full_unstemmed Elevated ratio of MMP2/MMP9 activity is associated with poor response to chemotherapy in osteosarcoma
title_short Elevated ratio of MMP2/MMP9 activity is associated with poor response to chemotherapy in osteosarcoma
title_sort elevated ratio of mmp2/mmp9 activity is associated with poor response to chemotherapy in osteosarcoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4793522/
https://www.ncbi.nlm.nih.gov/pubmed/26979530
http://dx.doi.org/10.1186/s12885-016-2266-5
work_keys_str_mv AT kunzpierre elevatedratioofmmp2mmp9activityisassociatedwithpoorresponsetochemotherapyinosteosarcoma
AT sahrheiner elevatedratioofmmp2mmp9activityisassociatedwithpoorresponsetochemotherapyinosteosarcoma
AT lehnerburkhard elevatedratioofmmp2mmp9activityisassociatedwithpoorresponsetochemotherapyinosteosarcoma
AT fischerchristian elevatedratioofmmp2mmp9activityisassociatedwithpoorresponsetochemotherapyinosteosarcoma
AT seebachelisabeth elevatedratioofmmp2mmp9activityisassociatedwithpoorresponsetochemotherapyinosteosarcoma
AT fellenbergjorg elevatedratioofmmp2mmp9activityisassociatedwithpoorresponsetochemotherapyinosteosarcoma